2019 International Congress » Huntington’s Disease

1:45pm-3:15pm

7,8- Dihydroxyflavone prevents 3-NitropropionicAcid (3-NP)-induced Striatal Toxicity by Modulating the TrkB receptor and Microglial Activation Pathway

S. Ahmed, M. Kwatra, VGM. Naidu (Kamrup, India)

1:45pm-3:15pm

A global survey on speech language therapists’ awareness to Huntington’s disease

A. Nuzzi, S. Naor, N. Inbar, T. Gurevich, Y. Manor (Santeramo In Colle, Italy)

1:45pm-3:15pm

A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease

S. Tabrizi, B. Leavitt, P. Sanwald Ducray, E. Wild, V. Schlegel, G. Hooper, A. Nicotra, J. Chevure, A. Smith, R. Lane, F. Bennett, L. Boak, R. Doody, S. Schobel (London, United Kingdom)

1:45pm-3:15pm

A Unified Staging System for Prodromal and Manifest Huntington’s disease

A. Mohan, Z. Sun, S. Ghosh, Y. Li, Y. Cheng, J. Hu, C. Sampaio (Yorktown Heights, NY, USA)

1:45pm-3:15pm

Ancillary Service Utilization and Impact in Huntington’s Disease

J. Yomtoob, C. Yeh, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm

Assessment of Caregiver Burden in Huntington’s disease

M. Yu, K. Tan, K. Koloms, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm

Assessment of Gait in Huntington’s disease patients using EncephaLog smartphone’s application

NI. Inbar, N. Omer, A. Bar David, N. Geva, I. Dabakarov, L. Barsky, Z. Yekutieli, N. Giladi, T. Gurevich (Tel Aviv, Israel)

1:45pm-3:15pm

Brain MRI Volume Changes after 12 months laquinimod treatment of Huntington disease (LEGATO-HD)

R. Reilmann, M. Gordon, A. Feigin, K. Anderson, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, N. Hobbs, R. Manber, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Victoria, Australia)

1:45pm-3:15pm

Burden of Huntington’s disease in the US: Analysis of an insured population

K. Raimundo, J. Luo, R. Tan, T. To, R. Fuller, J. Warner (South San Francisco, CA, USA)

1:45pm-3:15pm

Can we hear pathology in premanifest Huntington’s disease? Acoustic and listener-based analysis of speech

J. Chan, C. Shirbin, J. Stout, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm

Cerebellar Ataxia in Patients with Huntington’s Disease, an underestimated symptom?

GLF. Franklin, HAT. Teive, FBG. Germiniani, SR. Raskin, GMP. Pavanelli, SSM. Milano, NSL. Lima, OPB. Barsottini, JLP. Pedroso, FAM. Maggi, VT. Tumas, PMC. Carvalho, PCA. Azevedo, ILC. Lopes-Cendes (Curitiba, Brazil)

1:45pm-3:15pm

Changes in GABAergic transmission of striatal neurons in presymptomatic Huntington’s Disease

M. Treven, F. Zirpel, I. Mody (Vienna, Austria)

1:45pm-3:15pm

Characterization of impulsivity in Colombian patients with Huntington’s disease

L. Colmenares, C. Rodriguez, W. Fernandez (Bogotá, Colombia)

1:45pm-3:15pm

Comorbidities and medications in Huntington’s disease, Parkinson’s disease and the general population in a US claims database

L. Ishihara, E. Wild, D. Oliveri (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm

Correlation between structural neuroimaging and clinical outcomes in a small sample of patients with early Huntington’s disease

C. Estevez Fraga, E. Johnson, F. Rodrigues, P. Zeun, N. Hobbs, E. Rees, R. Roos, B. Landwehrmeyer, A. Durr, S. Gregory, R. Scahill, G. Rees, S. Tabrizi (London, United Kingdom)

1:45pm-3:15pm

Digital monitoring of Huntington’s disease with smartphone and smartwatch wearable technology: The Digital-HD study

R. Tortelli, T. Kilchenmann, F. Rodrigues, L. Byrne, A. Bamdadian, F. Lipsmeier, S. Schobel, M. Lindemann, E. Wild (London, United Kingdom)

1:45pm-3:15pm

Electroconvulsive Therapy (ECT): An Effective Option for the Treatment of Medication-Resistant Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature

J. Adrissi, N. Nadkarni, E. Gausche, D. Bega (Chicago, IL, USA)

1:45pm-3:15pm

Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD

B. Leavitt, A. Vallès, A. Stam, C. Brouwers, V. Fodale, A. Bresciani, A. Hill, A. Yung, B. Russell-Schulz, P. Kozlowski, A. Mackay, D. Ma, F. Beg, J. Higgins, S. van Deventer, M. Evers, P. Konstantinova (Vancouver, BC, Canada)

1:45pm-3:15pm

Factors underlying reduced aerobic capacity in Huntington disease

A. Rao, S. Norris, J. Montes, P. Wasserman, K. Marder (New York, NY, USA)

1:45pm-3:15pm

Gene Expression Profiling of depression in Huntington’s disease

G. Colpo, N. Rocha, E. Furr Stimming, A. Lucio (Houston, TX, USA)

1:45pm-3:15pm

Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease

S. Martinez-Horta, F. Sampedro, J. Perez-Perez, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)

1:45pm-3:15pm

Homozygous Huntington’s disease with two reduced penetrance alleles: A Case Report

K. Grimm, C. Zühlke, C. Gerloff, S. Zittel (Hamburg, Germany)

1:45pm-3:15pm

Huntington’s Disease Protein Huntingtin Associates with its own mRNA

M. Rakhimova, M. Daropova (Tashkent, Uzbekistan)

1:45pm-3:15pm

Huntington’s disease: A case review of Sub-Saharan Africans with diverse origins

M. Muthinja, J. Hooker (Nairobi, Kenya)

1:45pm-3:15pm

Impact of caring for patients with Huntington’s disease on work status

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (San Francisco, CA, USA)

1:45pm-3:15pm

Insomnia as clinical onset symptom in Juvenile Huntington’s Disease: Evaluation of a Family

M. Gultekin (Kayseri, Turkey)

1:45pm-3:15pm

Intermediate CAG repeat length in the HTT gene and comorbidity – The SHAPE Study (Swedish-Huntingtin-Alleles-and-PhenotypE)

M. Ghazarian, E. Stattin, J. Sundblom, V. Niemelä (Uppsala, Sweden)

1:45pm-3:15pm

Involuntary movements with abnormal brain imaging: A Case Report

W. Webb, P. Chapman, V. Sung, M. Dean (Birmingham, AL, USA)

1:45pm-3:15pm

Magnetic Resonance Spectroscopy Evaluation of Neuronal Integrity and Astrocytosis in a Phase 2 Study of Laquinimod as a Treatment for Huntington Disease (LEGATO-HD)

B. Leavitt, R. Reilmann, M. Gordon, K. Anderson, A. Feigin, S. Tabrizi, J. Stout, P. Piccini, B. Russell-Schulz, A. Mackay, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Vancouver, BC, Canada)

1:45pm-3:15pm

Mobility Impairments in Huntington’s Disease due to Cognitive Dysfunction

M. Rakhimova, N. Yusupova (Tashkent, Uzbekistan)

1:45pm-3:15pm

MRI, Clinical, and Neuropathological Findings after Bilateral Intra-striatal Administration of rAAV5-miHTT in Non-human Primates

J. Higgins, B. Blits, L. Spronck, A. Valles-Sanchez, M. Evers, S. van Deventer, P. Konstantinova, M. de Haan (Lexington, MA, USA)

1:45pm-3:15pm

Multimodal characterization of the visual network in Huntington’s disease

O. Odish, S. Gregory, I. Mayer, J.. Mills, E. Johnson, R. Scahill, J. Rothwell, G. Rees, J. Long, S. Tabrizi, R. Roos, M. Orth (Leiden, Netherlands)

1:45pm-3:15pm

NBIA-like MRI findings in a patient with Huntington’s disease

T. Shimizu, T. Matsukawa, Y. Abe, H. Suga, N. Tominaga, M. Nagai, T. Iizuka, H. Ishiura, J. Mitsui, S. Tsuji, R. Hanajima, K. Nishiyama (Yonago, Japan)

1:45pm-3:15pm

Neuromelanin MRI detects monoaminergic cell loss in Huntington Disease Expansion Gene Carriers.

ER. de Natale, H. Wilson, G. Dervenoulas, F. Niccolini, SJ. Tabrizi, M. Politis (London, United Kingdom)

1:45pm-3:15pm

Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

P. Kashyap, S. Gupta (Darbhanga, India)

1:45pm-3:15pm

Normative Curves for Selected Unified Huntington Disease Rating Scale Measures

J. Mills, J. Long, A. Mohan, J. Ware, C. Sampaio (Iowa City, IA, USA)

1:45pm-3:15pm

Novel exploratory outcome assessments in GENERATION HD1

D. Trundell, S. Schobel, R. Roos, K. Anderson, A. Thobhani, G. Hooper, M. Nguyen, S. Tabrizi (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm

Patient and physician perspectives on the care and assistance needs in Huntington’s disease

K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (South San Francisco, CA, USA)

1:45pm-3:15pm

Prevalence of Huntington’s Disease in Sardinia, Italy

A. Muroni, MR. Murru, T. Ercoli, V. Melas, E. Casaglia, M. Melis, E. Cocco, G. Defazio (Cagliari, Italy)

1:45pm-3:15pm

Quantification of regional iron content with Susceptibility Weighted Imaging in Huntington Disease Expansion Gene Carriers

ER. de Natale, H. Wilson, G. Dervenoulas, F. Niccolini, SJ. Tabrizi, M. Politis (London, United Kingdom)

1:45pm-3:15pm

Quantitative Motor (Q-Motor) Assessments Suggest a Beneficial Central Effect of Laquinimod in a Phase II Study in Huntington Disease (LEGATO-HD)

R. Reilmann, M. Gordon, R. Schubert, K. Anderson, A. Feigin, S. Tabrizi, B. Leavitt, J. Stout, P. Piccini, B. Borowsky, G. Rynkowski, R. Volkinshtein, J. Savola, M. Hayden (Muenster, Germany)

1:45pm-3:15pm

Reliability, feasibility and validity of a novel digital monitoring platform assessing cognitive and motor symptoms in people with Stage I and II Huntington’s disease (HD)

F. Lipsmeier, C. Simillion, A. Atieh Bamdadian, A. Smith, S. Schobel, C. Gossens, P. Weydt, E. Wild, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm

Seeking regulatory feedback on novel clinical outcome assessments: a case example from the Huntington’s Disease – Regulatory Science Consortium (HD-RSC)

A. Mullin, R. Fuller, G. Stebbins, J. Stout, A. Robbins, P. Feigenbaum, M. Roche, E. Gantman, C. Sampaio, M. Brumfield (Tucson, AZ, USA)

1:45pm-3:15pm

Speech impairment as a marker of clinical changes in premanifest Huntington’s disease

J. Chan, Y. Lie, J. Stout, A. Vogel (Melbourne, Australia)

1:45pm-3:15pm

Subcortical atrophy is an early event in Huntington’s disease

N. Rocha, L. Latham, O. Charron, G. Papadimitropoulos, G. Colpo, L. Freeman, E. Furr Stimming, A. Teixeira (Houston, TX, USA)

1:45pm-3:15pm

Successful altruistic living kidney donation in a patient with Huntington’s disease

C. Cooper, S. Chen, B. Bernard, J. Goldman (Chicago, IL, USA)

1:45pm-3:15pm

Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of Huntington disease minipigs mediated by AAV5-miHTT gene therapy

A. Vallès-Sanchez, A. Stam, C. Brouwers, J. Klíma, B. Bohuslavová, R. Pintauro, M. Sogorb-Gonzalez, L. Paerels, V. Fodale, A. Bresciani, Z. Ellederová, B. Blits, J. Motlik, S. van Deventer, M. Evers, P. Konstantinova (Amsterdam, Netherlands)

1:45pm-3:15pm

The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD

J. Corey-Bloom, S. Aboufadel, I. Beltran-Najera, C. Snell, M. Williams, P. Gilbert (La Jolla, CA, USA)

1:45pm-3:15pm

The Roche HD Natural History Study – an external comparator by design

G. Hooper, G. Palermo, F. Hlavac, C. Finnegan, E. Frick, L. Boak, R. Doody, S. Schobel (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm

Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease

M. Evers, M. de Haan, A. Valles-Sanchez, E. Sawyer, S. Gill, R. Roos, S. van Deventer, P. Konstantinova, J. Higgins (Amsterdam, Netherlands)

1:45pm-3:15pm

Tumor Pathology in Patients with Huntington’s Disease in a Specialized Center of Buenos Aires, Argentina (Preliminary Data)

D. Dias, E. Gatto, J. Etcheverry, M. Cesarini, G. da Prat, F. Peralta Calderon (Capital Federal, Argentina)

1:45pm-3:15pm

Usefulness of Heart Rate Variability to Identify the Risk of Falling in Huntington’s Disease

C. Terroba-Chambi, D. Vigo, M. Merello (Buenos Aires, Argentina)

1:45pm-3:15pm

Using functional status to aid interpretation of cUHDRS scores in patients with Huntington’s disease

D. Trundell, G. Palermo, J. Long, B. Leavitt, S. Schobel, S. Tabrizi (Welwyn Garden City, United Kingdom)

1:45pm-3:15pm

What connectivity tells us about neurodegeneration in Huntington disease? A fMRI study

P. de Azevedo, M. Nogueira, L. Ribeiro, B. de Campos, R. Guimarães, L. Piovesana, F. Cendes, I. Lopes-Cendes, C. Yasuda (Campinas, Brazil)